Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu5” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030))

Muhammad Abdur Razzak; Kevin Tran; Roisin McCague; Kathy Sengmany; Jackson Kos; Monica Langiu; Bohan Li; Shane D. Hellyer; Karen J. Gregory

doi:10.1016/j.bcp.2026.118324

Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu₅” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030))

Muhammad Abdur Razzak
, Kevin Tran
, Roisin McCague
, Kathy Sengmany
, Jackson Kos
, Monica Langiu
, Bohan Li
, Shane D. Hellyer
, Karen J. Gregory

Drug Discovery Biology

Research output: Contribution to journal › Comment / Debate › Other › peer-review

Abstract

The authors regret that incorrect details were provided upon publication for the human mGlu₅ plasmid used to make the HEK293A-human mGlu₅ cell line described in this study. The correct plasmid is human mGlu₅ (transcript variant b) in pCMV6-entry vector (Origene, SC119648). The authors would like to apologise for any inconvenience caused.

Original language	English
Article number	118324
Number of pages	1
Journal	Biochemical Pharmacology
Volume	253
DOIs	https://doi.org/10.1016/j.bcp.2026.118324
Publication status	Published - Nov 2026

Access to Document

10.1016/j.bcp.2026.118324Licence: CC BY

Cite this

Razzak, M. A., Tran, K., McCague, R., Sengmany, K., Kos, J., Langiu, M., Li, B., Hellyer, S. D., & Gregory, K. J. (2026). Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu₅” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030)). Biochemical Pharmacology, 253, Article 118324. https://doi.org/10.1016/j.bcp.2026.118324

@article{2b7df100cc3f4884b32b0b0bfbed93ef,

title = "Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu5” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030))",

abstract = "The authors regret that incorrect details were provided upon publication for the human mGlu5 plasmid used to make the HEK293A-human mGlu5 cell line described in this study. The correct plasmid is human mGlu5 (transcript variant b) in pCMV6-entry vector (Origene, SC119648). The authors would like to apologise for any inconvenience caused.",

author = "Razzak, \{Muhammad Abdur\} and Kevin Tran and Roisin McCague and Kathy Sengmany and Jackson Kos and Monica Langiu and Bohan Li and Hellyer, \{Shane D.\} and Gregory, \{Karen J.\}",

note = "Publisher Copyright: {\textcopyright} 2026 The Author(s)",

year = "2026",

month = nov,

doi = "10.1016/j.bcp.2026.118324",

language = "English",

volume = "253",

journal = "Biochemical Pharmacology",

issn = "0006-2952",

publisher = "Elsevier",

}

Razzak, MA, Tran, K, McCague, R, Sengmany, K, Kos, J, Langiu, M, Li, B, Hellyer, SD & Gregory, KJ 2026, 'Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu₅” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030))', Biochemical Pharmacology, vol. 253, 118324. https://doi.org/10.1016/j.bcp.2026.118324

Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu₅” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030)). / Razzak, Muhammad Abdur; Tran, Kevin; McCague, Roisin et al.
In: Biochemical Pharmacology, Vol. 253, 118324, 11.2026.

Research output: Contribution to journal › Comment / Debate › Other › peer-review

TY - JOUR

T1 - Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu5” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030))

AU - Razzak, Muhammad Abdur

AU - Tran, Kevin

AU - McCague, Roisin

AU - Sengmany, Kathy

AU - Kos, Jackson

AU - Langiu, Monica

AU - Li, Bohan

AU - Hellyer, Shane D.

AU - Gregory, Karen J.

PY - 2026/11

Y1 - 2026/11

N2 - The authors regret that incorrect details were provided upon publication for the human mGlu5 plasmid used to make the HEK293A-human mGlu5 cell line described in this study. The correct plasmid is human mGlu5 (transcript variant b) in pCMV6-entry vector (Origene, SC119648). The authors would like to apologise for any inconvenience caused.

AB - The authors regret that incorrect details were provided upon publication for the human mGlu5 plasmid used to make the HEK293A-human mGlu5 cell line described in this study. The correct plasmid is human mGlu5 (transcript variant b) in pCMV6-entry vector (Origene, SC119648). The authors would like to apologise for any inconvenience caused.

UR - https://www.scopus.com/pages/publications/105046793276

U2 - 10.1016/j.bcp.2026.118324

DO - 10.1016/j.bcp.2026.118324

M3 - Comment / Debate

C2 - 42570525

AN - SCOPUS:105046793276

SN - 0006-2952

VL - 253

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

M1 - 118324

ER -

Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu₅” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030))

Abstract

Access to Document

Other files and links

Pharmacological characterisation of allosteric modulators at human mGlu₅

Finely tuned glutamate receptor inhibitors as novel therapeutics for neurodegenerative disorders

Exploring metabotropic glutamate receptor 5 bias, allostery and heteromers

Cite this

Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu5” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030))

Abstract

Access to Document

Other files and links

Research output

Pharmacological characterisation of allosteric modulators at human mGlu5

Projects

Finely tuned glutamate receptor inhibitors as novel therapeutics for neurodegenerative disorders

Exploring metabotropic glutamate receptor 5 bias, allostery and heteromers

Cite this

Corrigendum to “Pharmacological characterisation of allosteric modulators at human mGlu₅” [Biochem. Pharmacol. 239 (2025) 117030] (Biochemical Pharmacology (2025) 239, (S0006295225002953), (10.1016/j.bcp.2025.117030))

Pharmacological characterisation of allosteric modulators at human mGlu₅